[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Cancer/Tumor Profiling Market Size study, by Technology (Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and other technologies) Cancer type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal cancer, melanoma cancer and other cancer) Applications (Clinical Application and Research Applications) and Regional Forecasts 2019-2026.

July 2019 | 200 pages | ID: GAB052F0971EN
Bizwit Research & Consulting LLP

US$ 3,160.00 US$ 3,950.00 -20 %
Offer valid until January 20, 2020!

E-mail Delivery (PDF), Hard Copy Mail Delivery

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Global Cancer/Tumor Profiling Market is valued approximately USD 5.9 billion in 2018 and is anticipated to grow with a healthy growth rate of more than 10.7 % over the forecast period 2019-2026. Growing focus for the development of personalized medicine, growing utility of biomarkers in tumor profiling and increasing R&D investments in cancer are some major trends that are responsible for the wide adoption of Cancer/Tumor Profiling globally.
Global Cancer/Tumor Profiling market is majorly driven by increasing prevalence of cancer globally. The World Cancer Research Fund International (WCRFI) estimates that, nearly 2 million new cases of breast cancer are being detected every year and breast cancer is considered as the most common form of cancer in women globally. American Cancer Research Society (ACRS) anticipates by 2030, incident rate of breast cancer is expected to reach over 9.9million cases with over 5.5million annual deaths, primarily due to aging population. Incident rates of breast cancer are highest (46% in 2016) amongst women aged between 45-65 years across the globe. ACRS studies reveals that, with aging population prevalence rate of breast cancer amongst elderly women aged 55 years and above is bound to increase. Breast cancer represents 12% of all new cases of cancer amongst women in 2016, according to WCRFI. Europe leads the world with highest number (25% in 2016) of new breast cancer cases in the world followed by North America and Asia Pacific according to National Cancer Institute (NCI), USA. Belgium, Denmark, France, Netherlands, Bahamas and USA are countries with highest rates of breast cancer in the world according to WCRFI survey in 2016. Global economic burden due to breast cancer stood at $5.7billion in 2016 according to ACRS. However, ACRS estimates, the economic burden on breast cancer is anticipated to reach over $8 billion by 2026. Increasing number of breast cancer cases would supplement global cancer/tumor profiling market for the forecasted period. However, lack of skilled professionals is a major factor that impede the growth of the Cancer/Tumor Profiling market over the forecast period.
On the basis of segmentation, the Cancer/Tumor Profiling market is segmented into technology, cancer type and application. The technology segment of global Cancer/Tumor Profiling market is classified into immunoassays, hybridization, next generation sequencing, mass spectrometry and other technologies of which immunoassays accounted for the largest market share owing to its cost-effectiveness, high sensitivity as well as technological advancements in this technology would propel the growth of the immunoassays. Based on the cancer type segment, the cancer/tumor profiling is bifurcated into breast cancer, lung cancer, prostate cancer, colorectal cancer, melanoma cancer and other cancer of which breast cancer segment holds the leading position owing to the increased awareness about breast cancer diagnosis, rising prevalence of breast cancer. The application segment includes clinical application and research application.

The regional analysis of Cancer/Tumor Profiling Market is considered for the key regions such as North America, Europe, Asia Pacific, Latin America and ROW. North America have occupied major share in the global Cancer/Tumor Profiling market. The major reasons for the dominance of North America are rising prevalence of cancer along with the high rate of adoption in this region. Whereas, Asia-Pacific is expected to emerge as the fastest growing region in terms of market share. The growth of Asia-Pacific region is witnessed owing to rising number of contract research organizations (CROs), growing demand for better healthcare services and increasing incidences of cancer.
The leading market players mainly include-

Illumina, Inc.
Qiagen N.V.
Neogenomics Laboratories, Inc.
HTG Molecular Diagnostics, Inc.
Genomic Health Inc.
Caris Life Sciences
Helomics Corporation
Nanostring Technologies, Inc.
Oxford Gene Technology
Ribomed Biotechnologies, Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Technology:
Immunoassays
Hybridization
Next Generation Sequencing
Mass Spectrometry
Other Technologies
By Cancer Type:
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma Cancer
Others Cancer
By Application:
Clinical Application
Research Application
By Regions:
North America
U.S.
Canada
Europe
UK
Germany
ROE
Asia Pacific
China
India
Japan
ROAPEC
LAMEA
Brazil
Mexico
ROW
Middle East & Africa

Furthermore, years considered for the study are as follows:

Historical year – 2016, 2017
Base year – 2018
Forecast period – 2019 to 2026

Target Audience of the Global Cancer/Tumor Profiling Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
CHAPTER 1.EXECUTIVE SUMMARY

1.1.Market Snapshot
1.2.Key Trends
1.3.Global & Segmental Market Estimates & Forecasts, 2016-2026 (USD Billion)
  1.3.1.Urgent Care Center Market, by Service, 2016-2026 (USD Billion)
  1.3.2.Urgent Care Center Market, by Ownership, 2016-2026 (USD Billion)
  1.3.3.Urgent Care Center Market, by Region, 2016-2026 (USD Billion)
1.4.Estimation Methodology
1.5.Research Assumption

CHAPTER 2.GLOBAL URGENT CARE CENTER MARKET DEFINITION AND SCOPE

2.1.Objective of the Study
2.2.Market Definition & Scope
  2.2.1.Industry Evolution
  2.2.2.Scope of the Study
2.3.Years Considered for the Study
2.4.Currency Conversion Rates

CHAPTER 3.GLOBAL URGENT CARE CENTER MARKET DYNAMICS

3.1.See Saw Analysis
  3.1.1.Market Drivers
  3.1.2.Market Challenges
  3.1.3.Market Opportunities

CHAPTER 4.GLOBAL URGENT CARE CENTER MARKET INDUSTRY ANALYSIS

4.1.Porter’s 5 Force Model
  4.1.1.Bargaining Power of Buyers
  4.1.2.Bargaining Power of Suppliers
  4.1.3.Threat of New Entrants
  4.1.4.Threat of Substitutes
  4.1.5.Competitive Rivalry
  4.1.6.Futuristic Approach to Porter’s 5 Force Model
4.2.PEST Analysis
  4.2.1.Political Scenario
  4.2.2.Economic Scenario
  4.2.3.Social Scenario
  4.2.4.Technological Scenario
4.3.Key Buying Criteria (On Demand)
4.4.Regulatory Framework (On Demand)
4.5.Investment Vs Adoption Scenario (On Demand)
4.6.Analyst Recommendation & Conclusion

CHAPTER 5.GLOBAL CANCER/TUMOUR PROFILING MARKET, BY TECHNOLOGY

5.1.Market Snapshot
5.2.Market Performance - Potential Model
5.3.Global Cancer/Tumour Profiling Market, Sub Segment Analysis
  5.3.1. Immunoassays
    5.3.1.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    5.3.1.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
  5.3.2. Hybridization
    5.3.2.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    5.3.2.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
  5.3.3.Next Generation Sequencing
    5.3.3.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    5.3.3.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
  5.3.4.Mass Spectrometry
    5.3.4.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    5.3.4.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
  5.3.5. Other Technologies
    5.3.5.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    5.3.5.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)

CHAPTER 6.GLOBAL CANCER/TUMOUR PROFILING MARKET, BY CANCER TYPE

6.1.Market Snapshot
6.2.Market Performance - Potential Model
6.3.Global Cancer/Tumour Profiling Market, Sub Segment Analysis
  6.3.1. Lung Cancer
    6.3.1.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    6.3.1.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
  6.3.2. Breast Cancer
    6.3.2.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    6.3.2.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
  6.3.3. Colorectal Cancer
    6.3.3.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    6.3.3.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
  6.3.4. Prostate Cancer
    6.3.4.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    6.3.4.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
  6.3.5. Melanoma Cancer
    6.3.5.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    6.3.5.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
  6.3.6. Other Cancers
    6.3.6.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    6.3.6.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)

CHAPTER 7.GLOBAL CANCER/TUMOUR PROFILING MARKET, BY APPLICATION

7.1.Market Snapshot
7.2.Market Performance - Potential Model
7.3.Global Cancer/Tumour Profiling Market, Sub Segment Analysis
  7.3.1. Clinical Application
    7.3.1.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    7.3.1.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
  7.3.2. Research Application
    7.3.2.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    7.3.2.2.Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)

CHAPTER 8.GLOBAL CANCER/TUMOUR PROFILING MARKET, BY REGIONAL ANALYSIS

8.1.Cancer/Tumour Profiling Market, Regional Market Snapshot (2016-2026)
8.2.North America Cancer/Tumour Profiling Market Snapshot
  8.2.1.U.S.
    8.2.1.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    8.2.1.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.2.1.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.2.1.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
  8.2.2.Canada
    8.2.2.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    8.2.2.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.2.2.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.2.2.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.Europe Cancer/Tumour Profiling Market Snapshot
  8.3.1.U.K.
    8.3.1.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    8.3.1.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.3.1.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.3.1.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
  8.3.2.Germany
    8.3.2.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    8.3.2.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.3.2.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.3.2.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
  8.3.3.Rest of Europe
    8.3.3.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    8.3.3.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.3.3.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.3.3.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.Asia Cancer/Tumour Profiling Market Snapshot
  8.4.1.China
    8.4.1.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    8.4.1.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.4.1.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.4.1.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
  8.4.2.India
    8.4.2.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    8.4.2.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.4.2.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.4.2.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
  8.4.3.Japan
    8.4.3.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    8.4.3.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.4.3.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.4.3.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
  8.4.4.Rest of Asia Pacific
    8.4.4.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    8.4.4.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.4.4.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.4.4.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.5.Latin America Cancer/Tumour Profiling Market Snapshot
  8.5.1.Brazil
    8.5.1.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    8.5.1.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.5.1.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.5.1.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
  8.5.2.Mexico
    8.5.2.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    8.5.2.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.5.2.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.5.2.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.6.Rest of The World
  8.6.1.Middle East and Africa
    8.6.1.1.Market estimates & forecasts, 2016-2026 (USD Billion)
    8.6.1.2.Technology breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.6.1.3.Cancer Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    8.6.1.4. Application breakdown estimates & forecasts, 2016-2026 (USD Billion)

CHAPTER 9.COMPETITIVE INTELLIGENCE

9.1.Company Market Share (Subject to Data Availability)
9.2.Top Market Strategies
9.3.Company Profiles
  9.3.1. Illumina, Inc.
    9.3.1.1.Overview
    9.3.1.2.Financial (Subject to Data Availability)
    9.3.1.3.Product Summary
    9.3.1.4.Recent Developments
  9.3.2. Qiagen N.V.
  9.3.3. Neogenomics Laboratories, Inc.
  9.3.4. HTG Molecular Diagnostics, Inc.
  9.3.5. Genomic Health Inc.
  9.3.6. Caris Life Sciences
  9.3.7. Helomics Corporation
  9.3.8. Nanostring Technologies, Inc.
  9.3.9. Oxford Gene Technology
  9.3.10.Ribomed Biotechnologies, Inc.

CHAPTER 10.RESEARCH PROCESS

10.1.Research Process
  10.1.1.Data Mining
  10.1.2.Analysis
  10.1.3.Market Estimation
  10.1.4.Validation
  10.1.5.Publishing
  10.1.6.Research Assumption


More Publications